✨ Free AI Report
IGC Pharma, Inc. (formerly India Globalization Capital, Inc.): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research IGC Pharma, Inc. (formerly India Globalization Capital, Inc.)
Company Research

IGC Pharma, Inc. (formerly India Globalization Capital, Inc.): Business Overview, Financials & Competitive Analysis

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company was formerly known as India Globalization Capital, Inc. and changed...

Analyst-debate audio for IGC Pharma, Inc. (formerly India Globalization Capital, Inc.)

AskCyborg analysts argue the bull and bear cases for IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Weak

Cyborg Score thesis

Speculative clinical-stage biotech with limited resources, high failure risk, but exposure to large Alzheimer's market if...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical Stage Pharmaceutical Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) Overview

Pro stress-test →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company has undergone significant strategic transformation from its original infrastructure commodities business to focus on innovative neurodegenerative disease therapeutics.

Strategic Profile

Pro stress-test →

The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's, with pre-clinical stage product candidates including TGR-63, IGC-M3, and LMP to treat Alzheimer's disease. As a micro-cap biotech player, IGC Pharma is pursuing high-risk, high-reward clinical development in a large therapeutic market with significant unmet medical needs in Alzheimer's treatment.

Competitive Landscape

Pro stress-test →

IGC Pharma competes in the crowded Alzheimer's therapeutics market against larger pharmaceutical companies and other biotech firms with greater resources. Competitors include companies developing cognitive decline treatments, agitation management therapies, and novel disease-modifying approaches. The company's micro-cap status and limited funding create competitive disadvantages versus well-capitalized rivals.

Industry Context

IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) operates in Biopharmaceutical / Clinical Stage Pharmaceutical Development.

Key facts

Founded: 2005 · Headquarters: Potomac, Maryland · Market cap: $26.04M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on IGC Pharma, Inc. (formerly India Globalization Capital, Inc.).

  • Company rebranded to IGC Pharma in March 2023, marking strategic pivot from diversified commodities to pure-play pharmaceutical focus
  • Lead candidate IGC-AD1 has reached Phase II trials, representing material clinical progress for a micro-cap biotech
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026IGC Pharma held Q4 2025 earnings call highlighting strategic focus on Alzheimer's disease treatments
  • 2026Phase 2 CALMA trial for IGC-AD1 reached 70% enrollment with expansion to new clinical trial sites
  • +1 moreTrack every material event for IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) as it happens. Explore monitoring →
Get alerted when IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Lecanemab (Leqembi)Approved amyloid-targeting monoclonal antibody for early Alzheimer's→DonanemabInvestigational amyloid-targeting antibody in late-stage development→Various antipsychotic/behavioral therapiesStandard treatments for agitation in dementia→

Compare IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) operates in Biopharmaceutical / Clinical Stage Pharmaceutical Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Clinical Stage Pharmaceutical Development research →
NEW · MCP server

Ask your AI assistant about IGC Pharma, Inc. (formerly India Globalization Capital, Inc.)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) and its top competitor on Cyborg Score”
“What did IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) do this quarter?”
“Is IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) do?+
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company was formerly known as India Globalization Capital, Inc. and changed...
What is IGC Pharma, Inc. (formerly India Globalization Capital, Inc.)'s Cyborg Score?+
IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are IGC Pharma, Inc. (formerly India Globalization Capital, Inc.)'s main competitors?+
Named competitors include Lecanemab (Leqembi), Donanemab, Various antipsychotic/behavioral therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score